ArticleScientific reports2017
Mechanistic platform knowledge of concomitant sugar uptake in Escherichia coli BL21(DE3) strains.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- A Guideline to Set Up Cascaded Continuous Cultivation with E. coli Bl21 (DE3).Methods in molecular biology (Clifton, N.J.) · 2022Guideline
- Bi-directionalized promoter systems allow methanol-free production of hard-to-express peroxygenases with Komagataella Phaffii.Microbial cell factories · 2024Article
- Use of the mCherry fluorescent protein to optimize the expression of class I lanthipeptides in Escherichia coli.Microbial cell factories · 2023Article
- Improving CoQMicrobial cell factories · 2021Article
- Production of soluble regulatory hydrogenase from Ralstonia eutropha in Escherichia coli using a fed-batch-based autoinduction system.Microbial cell factories · 2021Article
- Cascaded processing enables continuous upstream processing with E. coli BL21(DE3).Scientific reports · 2021Article
- A Gram-Scale Limonene Production Process with EngineeredMolecules (Basel, Switzerland) · 2020Article
- The Effects of Lactose Induction on a Plasmid-FreeBioengineering (Basel, Switzerland) · 2020Article
- Repetitive Fed-Batch: A Promising Process Mode for Biomanufacturing WithFrontiers in bioengineering and biotechnology · 2020Article
- The LazarusFrontiers in bioengineering and biotechnology · 2020Article
- Growth-dependent recombinant product formation kinetics can be reproduced through engineering of glucose transport and is prone to phenotypic heterogeneity.Microbial cell factories · 2019Article
- Perspectives of inclusion bodies for bio-based products: curse or blessing?Applied microbiology and biotechnology · 2019Review
- The Rocky Road From Fed-Batch to Continuous Processing WithFrontiers in bioengineering and biotechnology · 2019Review
- Inclusion Body Bead Size inMicroorganisms · 2018Article
- E. coli HMS174(DE3) is a sustainable alternative to BL21(DE3).Microbial cell factories · 2018Article
- Teaching an old pET new tricks: tuning of inclusion body formation and properties by a mixed feed system in E. coli.Applied microbiology and biotechnology · 2018Article
- Impact of Glycerol as Carbon Source onto Specific Sugar and Inducer Uptake Rates and Inclusion Body Productivity in E. coli BL21(DE3).Bioengineering (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When producing recombinant proteins, the use of Escherichia coli strain BL21(DE3) in combination with the T7-based pET-expression system is often the method of choice. In a recent study we introduced a mechanistic model describing the correlation of the specific glucose uptake rate (q
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.